Yadvir Garg1, Neha Kakria2, C D S Katoch3, D Bhattacharyya4. 1. Classified Specialist (Respiratory Medicine), Military Hospital (Cardio Thoracic Centre), Pune 411040, India. 2. Graded Specialist (Radiology), Command Hospital (Southern Command), Pune 411040, India. 3. Senior Advisor (Medicine & Respiratory Medicine) & Head, Military Hospital (Cardio Thoracic Centre), Pune 411040, India. 4. Consultant (Medicine & Respiratory Medicine) & Head, Army Hospital (R&R), Delhi 110010, India.
Abstract
BACKGROUND: Evidence regarding the role of non-invasive marker of airway inflammation, fractional exhaled nitric oxide (FeNO) to guide asthma treatment is equivocal. We aimed to evaluate if the use of FeNO to adjust inhaled corticosteroid treatment resulted in reduced daily corticosteroid use and lesser exacerbations. METHODS: 100 patients of bronchial asthma in the age group of 12-70 years were randomised to receive inhaled corticosteroids based on either FeNO measurements (n = 50) or as per Global Initiative for Asthma (GINA) guidelines. Follow up was done every 2 months for period of 12 months. Results were compared in terms of mean daily inhaled corticosteroid use and number of exacerbations. RESULTS: After the follow up period of 12 months, mean daily dose of ICS (SD) required in FeNO group was 267.5 μg (126.29), as opposed to control group in which mean daily dose of steroid was 320.00 μg (138.69). However this observed difference in steroid dose was statistically insignificant (p value = 0.061). The estimated mean (SD) rate of asthma exacerbation experienced in follow up period of 12 months in FeNO group was 0.3 episodes (0.54) per patient per year (95% confidence interval, 0.145-455) and 0.4 episodes (0.61) per patient per year in control group (95% confidence interval, 0.228-572). However this difference in rate of exacerbations between the two study groups was not statistically significant (p = 0.387). CONCLUSION: FeNO guided management strategy for asthma did not result in statistically significant reduction in dose of inhaled corticosteroids or number of asthma exacerbations.
BACKGROUND: Evidence regarding the role of non-invasive marker of airway inflammation, fractional exhaled nitric oxide (FeNO) to guide asthma treatment is equivocal. We aimed to evaluate if the use of FeNO to adjust inhaled corticosteroid treatment resulted in reduced daily corticosteroid use and lesser exacerbations. METHODS: 100 patients of bronchial asthma in the age group of 12-70 years were randomised to receive inhaled corticosteroids based on either FeNO measurements (n = 50) or as per Global Initiative for Asthma (GINA) guidelines. Follow up was done every 2 months for period of 12 months. Results were compared in terms of mean daily inhaled corticosteroid use and number of exacerbations. RESULTS: After the follow up period of 12 months, mean daily dose of ICS (SD) required in FeNO group was 267.5 μg (126.29), as opposed to control group in which mean daily dose of steroid was 320.00 μg (138.69). However this observed difference in steroid dose was statistically insignificant (p value = 0.061). The estimated mean (SD) rate of asthma exacerbation experienced in follow up period of 12 months in FeNO group was 0.3 episodes (0.54) per patient per year (95% confidence interval, 0.145-455) and 0.4 episodes (0.61) per patient per year in control group (95% confidence interval, 0.228-572). However this difference in rate of exacerbations between the two study groups was not statistically significant (p = 0.387). CONCLUSION: FeNO guided management strategy for asthma did not result in statistically significant reduction in dose of inhaled corticosteroids or number of asthma exacerbations.
Authors: F H Guo; S A Comhair; S Zheng; R A Dweik; N T Eissa; M J Thomassen; W Calhoun; S C Erzurum Journal: J Immunol Date: 2000-06-01 Impact factor: 5.422
Authors: Stanley J Szefler; Herman Mitchell; Christine A Sorkness; Peter J Gergen; George T O'Connor; Wayne J Morgan; Meyer Kattan; Jacqueline A Pongracic; Stephen J Teach; Gordon R Bloomberg; Peyton A Eggleston; Rebecca S Gruchalla; Carolyn M Kercsmar; Andrew H Liu; Jeremy J Wildfire; Matthew D Curry; William W Busse Journal: Lancet Date: 2008-09-20 Impact factor: 79.321
Authors: Mariëlle W Pijnenburg; E Marije Bakker; Wim C Hop; Johan C De Jongste Journal: Am J Respir Crit Care Med Date: 2005-06-23 Impact factor: 21.405
Authors: William J Calhoun; Bill T Ameredes; Tonya S King; Nikolina Icitovic; Eugene R Bleecker; Mario Castro; Reuben M Cherniack; Vernon M Chinchilli; Timothy Craig; Loren Denlinger; Emily A DiMango; Linda L Engle; John V Fahy; J Andrew Grant; Elliot Israel; Nizar Jarjour; Shamsah D Kazani; Monica Kraft; Susan J Kunselman; Stephen C Lazarus; Robert F Lemanske; Njira Lugogo; Richard J Martin; Deborah A Meyers; Wendy C Moore; Rodolfo Pascual; Stephen P Peters; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stanley J Szefler; Stephen I Wasserman; Michael J Walter; Michael E Wechsler; Homer A Boushey Journal: JAMA Date: 2012-09-12 Impact factor: 56.272
Authors: Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft Journal: J Allergy Clin Immunol Date: 2004-01 Impact factor: 10.793
Authors: Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh Journal: J Allergy Clin Immunol Date: 2020-12 Impact factor: 10.793
Authors: Sumita B Khatri; Jonathan M Iaccarino; Amisha Barochia; Israa Soghier; Praveen Akuthota; Anna Brady; Ronina A Covar; Jason S Debley; Zuzana Diamant; Anne M Fitzpatrick; David A Kaminsky; Nicholas J Kenyon; Sandhya Khurana; Brian J Lipworth; Kevin McCarthy; Michael Peters; Loretta G Que; Kristie R Ross; Elena K Schneider-Futschik; Christine A Sorkness; Teal S Hallstrand Journal: Am J Respir Crit Care Med Date: 2021-11-15 Impact factor: 21.405